NCT04319484View on ClinicalTrials.gov

Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 2, 2020

Primary Completion Date

January 1, 2025

Study Completion Date

December 1, 2025

Conditions
Hepatocellular CarcinomaPortal Vein Tumor ThrombusLiver Transplantation
Interventions
DRUG

lenvatinib

1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.

DRUG

Placebo

1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT04319484 - Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Biotech Hunter | Biotech Hunter